Perrigo Company Company Profile (NYSE:PRGO)

Perrigo Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Perrigo Company declared a quarterly dividend on Wednesday, May 3rd. Investors of record on Friday, May 26th will be paid a dividend of $0.16 per share on Tuesday, June 13th. This represents a $0.64 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date of this dividend is Wednesday, May 24th. View Perrigo Company's Dividend History.

Perrigo Company (NYSE:PRGO) released its earnings results on Tuesday, May, 30th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.06. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.19 billion. Perrigo Company had a positive return on equity of 11.79% and a negative net margin of 43.81%. Perrigo Company's revenue was down 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.32 EPS. View Perrigo Company's Earnings History.

Perrigo Company updated its FY17 earnings guidance on Tuesday, May, 30th. The company provided earnings per share (EPS) guidance of $4.15-4.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.30. The company issued revenue guidance of $4.6-4.8 billion, compared to the consensus revenue estimate of $4.78 billion.

15 equities research analysts have issued twelve-month price targets for Perrigo Company's stock. Their predictions range from $60.00 to $125.00. On average, they anticipate Perrigo Company's stock price to reach $82.00 in the next year. View Analyst Ratings for Perrigo Company.

Here are some recent quotes from research analysts about Perrigo Company stock:

• 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: May 22, 2017, 23:13 ET Date and time of production: May 22, 2017, 22:26 ET Target Price / Valuation Methodology: Perrigo Company – PRGO Discounted cash flow analysis supports an $86 valuation for PRGO shares Our discounted cash flow (DCF) analysis leads us to a price target of $86/share for PRGO. Our DCF considers our estimates through 2021, low-single-digit growth through 2033 and zero terminal growth thereafter. In addition, we expect Perrigo’s margin structure to remain somewhat consistent with our 2021 estimates." (5/22/2017)
• 2. Deutsche Bank AG analysts commented, "We updated our model to reflect PRGO's divestiture of the Tysabri royalty stream to Royalty Pharma, which the company expects to complete this month, and preliminary assumptions for de-leveraging with the proceeds. The net effect of these changes was EPS dilution of ~15-20% over 2017-21 and a reduction in our DCF-derived PT to $87 (from $93), as our prior model reflected more value for the Tysabri royalty stream (~$3bn) relative to the upfront payment of $2.2bn. We have not factored in the potential sales-based milestone payments of $650mn, which could add ~$4/share to the theoretical DCF value if they hit. We continue to view PRGO as a unique asset with good value creation potential over the longer term, and are maintaining our Buy rating. Solid execution in the coming quarters will be critical for the stock, in our view." (3/14/2017)
• 3. Jefferies Group LLC analysts commented, "Unaudited Q4 results were ahead of forecast. But the real story is FY17 guidance and it disappointed even after sharp cuts to Street models just 4 weeks ago. For the first time we can recall both rev & EPS will decline ' not a good story line for an OTC-focused company. Tysabri's sale helps de-lever PRGO but at the same time shrinks the EPS base by ~$2.20. Mgt continues to make moves to enhance shareholder value ' but it may take quite some time to do so." (2/28/2017)
• 4. Royal Bank Of Canada analysts commented, "While we expected a challenging 2017 guide, it was worse than we anticipated and came with an unexpected CFO departure. The strategic review around whether to sell Rx/generics will linger, limiting visibility but the conundrum is that we do not see upside in either scenario. We remain on the sidelines with target down to $68. Several additional thoughts after speaking with management this evening." (2/28/2017)

Some companies that are related to Perrigo Company include Cerner Corporation (CERN), Mylan N.V. (MYL), AmerisourceBergen Corporation (Holding Co) (ABC), Quintiles Transitional Holdings (Q), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN), Eisai Co., Ltd (ESALY), Smith & Nephew SNATS (SNN), Quest Diagnostics Incorporated (DGX), IDEXX Laboratories (IDXX), Henry Schein (HSIC), DENTSPLY SIRONA (XRAY), Centene Corporation (CNC), Genmab A/S (GNMSF), Lonza Group Ag (LZAGY), Align Technology (ALGN), Olympus Corp. (OCPNY) and Hologic (HOLX).

Perrigo Company's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Manning & Napier Advisors LLC (1.80%), Fisher Asset Management LLC (0.32%), Chevy Chase Trust Holdings Inc. (0.09%), Cortland Associates Inc. MO (0.08%), Bank of Montreal Can (0.07%) and PGGM Investments (0.06%). Company insiders that own Perrigo Company stock include Gary K Kunkle Jr, Geoffrey M Parker, Herman Morris Jr, John T Hendrickson, Joseph C Papa, Judy L Brown, Michael J Jandernoa, Sharon Kochan, Thomas Farrington and Todd W Kingma. View Institutional Ownership Trends for Perrigo Company.

Perrigo Company's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, BB&T Corp, Sanders Morris Harris LLC, Exxonmobil Investment Management Inc. TX, Cortland Associates Inc. MO, Sumitomo Mitsui Asset Management Company LTD, Winslow Evans & Crocker Inc. and Xact Kapitalforvaltning AB. Company insiders that have sold Perrigo Company stock in the last year include Gary K Kunkle Jr, Herman Morris Jr, Judy L Brown and Thomas Farrington. View Insider Buying and Selling for Perrigo Company.

Perrigo Company's stock was purchased by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Aperio Group LLC, Mn Services Vermogensbeheer B.V., Bank of Montreal Can, Wealth Enhancement Advisory Services LLC, Middleton & Co Inc MA, Oregon Public Employees Retirement Fund and State of Alaska Department of Revenue. View Insider Buying and Selling for Perrigo Company.

Shares of Perrigo Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Perrigo Company stock can currently be purchased for approximately $76.24.